Gongwin Biopharm Holdings Co., Ltd. (TPEX:6617)

Market Cap	8.96B -37.3%
Revenue (ttm)	37.46M +17.9%
Net Income	-88.37M
EPS	-0.71
Shares Out	122.62M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	196,523
Average Volume	181,731
Open	73.10
Previous Close	73.10
Day's Range	71.20 - 73.10
52-Week Range	70.10 - 122.00
Beta	-0.04
RSI	31.56
Earnings Date	Mar 17, 2026

About Gongwin Biopharm Holdings

Gongwin Biopharm Holdings Co., Ltd., a clinical-stage biopharmaceutical company, develops anticancer drugs in Hong Kong, China, and Singapore. It is developing PTS302, which has completed Phase III clinical trials for the treatment of lung cancer; PTS100, which is in Phase II clinical trials for the treatment of hepatocellular carcinoma; PTS02, which is in Phase I clinical trials for the treatment of adenoid cystic carcinoma; and PTS500 for the treatment of malignant pleural effusion. The company also develops animal medicines; engaged in the p...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2014
• Country: Cayman Islands
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6617

Financial Performance

In 2024, Gongwin Biopharm Holdings's revenue was 32.04 million, an increase of 69.39% compared to the previous year's 18.92 million. Losses were -82.55 million, -10.31% less than in 2023.